HOME >> BIOLOGY >> NEWS
Researchers identify cell, genetic environment behind nerve-tissue tumors that lead to cancer

DALLAS May 3, 2002 Researchers at UT Southwestern Medical Center at Dallas believe they are hot on the trail of a way to prevent benign tumors that attack the nervous system and can be precursors to terminal cancer.

The research, published in todays edition of Science, reveals that tumors in neurofibromatosis 1 (NF-1) patients form out of a particular type of cell, the Schwann cell. Neurofibromatosis, also known as von Recklinghausen disease, is a genetic disorder that causes benign tumors to form on the nerves, skin and internal organs.

Neurofibromatosis is the most common neurological disorder caused by a single gene, and there are two distinct forms: NF-1, which affects multiple organ systems, including the central and peripheral nervous systems, and is present in about 1 in 3,500 people worldwide; and NF-2, which affects only the vestibular nerve, a cranial nerve related to hearing and balance, and the membranes around the brain and spinal cord. NF-2 is present in about 1 in 40,000 people worldwide.

The benign tumors, called neurofibromas, develop into malignant tumors, called neurofibrosarcomas, in 10 percent to 15 percent of NF-1 patients. The malignant tumors do not respond well to currently available treatments.

The new research describes genetically permissive and restrictive environments for NF-1 tumor development. The tumors grow in a permissive environment, but they are nonexistent when the environment is restrictive, researchers say.

Dr. Yuan Zhu, instructor in the Center for Developmental Biology and lead author of the study, said the findings could lead to a new approach to combating NF-1. Zhu has been studying neurofibromatosis since 1995, when as a graduate student he joined the lab of Dr. Luis Parada, director of the Center for Developmental Biology and senior author of the paper.

The focus has always been on attacking the tumor cells, Zhu said. But in our findings, killing the tumor cells is not t
'"/>

Contact: Wayne Carter
Wayne.Carter@UTSouthwestern.edu
214-648-3404
UT Southwestern Medical Center
2-May-2002


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
(Date:4/23/2014)... biomedical engineer at the University of Houston (UH) is ... transfusions safer. His work is supported by a $1.8 ... , Blood transfusions save millions of lives every ... Without them, for instance, routine surgeries would become life ... strong evidence that transfusions of red blood cells stored ...
(Date:4/22/2014)... to behave at the dinner tablecut up their food and ... Eating Behaviors , found that when 6-10 year old children ... such as drumsticks, whole apples, or corn on the cob ... cut. "They were twice as likely to disobey adults ... Professor and Director of the Cornell Food and Brand Lab. ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
Cached News: